Streamlined Reimbursement Processes by Both Public and Private Healthcare Providers Spurring Adoption of Transseptal Access Systems

ROCKVILLE, MARYLAND, UNITED STATES, June 14, 2024 /EINPresswire.com/ -- Fact.MR, a leading market research company, states that the global transseptal access system market is estimated to reach a valuation of US$ 1.14 billion in 2024 and expand at a CAGR of 9.7% from 2024 to 2034. Growing demand for transseptal access systems is being driven by the rising number of heart-related procedures being performed globally.

Get Free Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=10192

People with valvular heart disease, irregular cardiac rhythms, and coronary heart disease are frequently afflicted with left-sided heart failure. Transseptal access system instruments are extensively used for the surgical treatment of various conditions. As innovative products with enhanced features enter the market and medical technology progresses, demand for transseptal access methods is projected to rise at a significant pace during the forecast period.
Both public and private healthcare providers, facilitating reimbursement for diagnosis and treatment, are projected to contribute to the growth of the global healthcare insurance market in the foreseeable future. Emergence of novel treatments like left atrial appendage occlusion therapy, which has demonstrated significant benefits for numerous patients, is forecasted to drive market growth in the coming years.

Key Takeaways from Market Study

• The global transseptal access system market is forecasted to attain revenue of US$ 2.86 billion by the end of 2034.

• North America is evaluated to hold a market share of 48.6% by 2034.

• The Chile market is projected to expand at a CAGR of 11.7% from 2024 to 2034 and occupy a market share of 13.4% by 2034 in Latin America.

• Sales of transseptal access systems in Canada are evaluated to reach US$ 171.7 million by the end of 2034.

• Based on application, revenue from the mitral valve repair segment is forecasted to increase from US$ 336.2 million in 2024 to US$ 859.6 million by the end of 2034.

• The market in Latin America is analyzed to expand at a CAGR of 11.5% through 2034.

Continuous enhancements in sheath designs, focusing on improving trackability and hemostatic properties, are contributing to transseptal access system market growth by enhancing procedural efficiency and safety, says a Fact.MR analyst.

Top Key Players Profiled in this report are Boston Scientific Corporation; Medtronic Plc; Terumo Corporation; Merit Medical Systems; Cook Medical LLC; Abbott Laboratories; Baylis Medical Company Inc.; Transseptal Solutions Inc.

Heart Surgeries Becoming Easier Due with 3D Mapping Systems

Transseptal access systems have transformed many cardiac procedures by offering a less invasive pathway to the left atrium. As this method evolves, various innovative developments are further enhancing its safety, accuracy, and clinical utility.

One notable advancement involves integrating advanced imaging modalities such as intracardiac echocardiography and 3D mapping systems. These technologies provide real-time, high-resolution visualization of the transseptal puncture site and surrounding anatomy, improving procedural guidance and reducing complications.

Creation of specialized transseptal access devices with enhanced maneuverability, sheath lubrication, and puncture mechanisms is facilitating a smoother and more controlled process. Some devices even incorporate built-in safety features to minimize the risk of unintended punctures or perforations.
The transseptal approach is being explored for new applications beyond its traditional role in structural heart interventions. For example, it demonstrates potential in delivering catheter-based therapies for certain neurovascular disorders, broadening its therapeutic possibilities.

Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=10192

Recent Developments:-

• In February 2022, Boston Scientific Corporation announced the acquisition of Baylis Medical Company Inc. This firm supplies guidewires, sheaths, and dilators needed for catheter-based left-heart surgeries in addition to state-of-the-art transseptal access solutions.

• For patients with mitral valve dysfunction, the privately held medical device company Cephea Valve Technologies, Inc. creates minimally invasive heart valve replacement options. Abbott declared in January 2019 that it had fulfilled its option to buy the business.

Explore More Related Studies Published by Fact.MR Research:

Transcatheter Heart Valve Replacement Market: Worldwide revenue from transcatheter heart valve replacement is expected to be US$ 5.31 billion in 2024, with a projected CAGR of 13.9% reaching US$ 19.43 billion by 2034. This growth is driven by the increasing prevalence of heart disorders globally.

Heart Valve Devices Market: The global heart valve devices market is expected to be valued at US$ 11.16 billion in 2022, up from US$ 9.85 billion in 2021, marking a 13.3% year-over-year increase. From 2022 to 2032, sales are projected to grow at a CAGR of 13%, reaching US$ 37.5 billion by 2032.

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the transseptal access system market for 2019 to 2023 and forecast statistics for 2024 to 2034.
The study divulges essential insights into the market based on product (transseptal access needles, transseptal access sheaths), application (atrial fibrillation ablation, mitral valve repair, left atrial appendage occlusion), and end user (hospitals, ambulatory surgical centers, specialty clinics), across seven major regions of the world (North America, Latin America, Eastern Europe, Western Europe, East Asia, South Asia & Pacific, and MEA).

About Fact.MR:

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.

Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Sales Team: sales@factmr.com

S. N. Jha
Fact.MR
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.